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SYSTEM AND METHOD FOR INTRANASAL
ADMINISTRATION OF LORAZEPAM

contrast, intranasal administration is perceived as non

This Application is a Continuation-in-Part of co-pending
application Ser. No. 09/569,125, ?led May 10, 2000, noW

invasive, is not accompanied by pain, has no signi?cant
after-effects and produces the grati?cation of prompt relief
in the patient exhibiting the symptom. This is of particular
advantage When the patient is a child. Most people have

abandoned.

some familiarity With nasal sprays in the form of over-the

counter decongestants for alleviating the symptoms of colds
FIELD OF THE INVENTION

and allergies that they or a family member have used

The invention relates to pharmaceutical drug composi
tions and preparations of loraZepam. This invention also

routinely. Another important consideration is that the patient
10

to devices for the intranasal administration of loraZepam.
BACKGROUND OF THE INVENTION

LoraZepam preparations for the treatment of anxiety

15

related disorders and to induce sedation have been previ

medicated solution can be given to the patient to practice the
technique for proper insertion, inhalation and activation for
self-administration.
In vieW of the aforementioned advantages and bene?ts
afforded by the intranasal administration, it Would be

expected that a preparation of loraZepam exhibiting systemic
pharmacological activity Would presently be available for

ously approved by the US. Food and Drug Administration
(“FDA”) and have been long-used for oral, intramuscular
and/or intravenous administration. LoraZepam is currently

intranasal administration. This has not occurred, despite the
fact that preparations for oral, IM and IV administration

marketed in injectable and tablet formulations. Marketers of

have been approved for commercial use for many years.
Despite the remarkable commercial success that has been

these preparations have not sought regulatory approval from
the FDA for liquid compositions of the same therapeutic
compound for intranasal administration. This is surprising
since it is Well-knoWn from the literature that the intranasal
administration of a pharmacologically active compound
generally results in a more rapid bioavailability of the
compound, or of its desired active metabolite than if the

can self-administer the prescribed dosage(s) of nasal spray.
An empty nasal spray device, or one containing a non

relates to pharmaceutical drug delivery devices, speci?cally

enjoyed by those drugs that have been made available in
25

compound is administered orally. Moreover, the time

intranasal form, in fact, only a very limited number of
compounds are commercially available to physicians to
prescribe and dispense to their patients in that form.
Furthermore, only one multiple-dose spray device has

apparently been approved by the FDA for intranasal admin

required to achieve the same concentration of the active
compound in the bloodstream e.g., Within a period of about

istration of an opiate solution that is categoriZed as a
controlled substance. The devices that are presently avail
thirty minutes after administration, is generally less via the
able exhibit several de?ciencies. One spray device intended
intranasal route compared to oral administration.
for multiple uses must be primed before use by expelling a
portion of the liquid contents in order to assure that the pump
It has been reported that, folloWing oral administration,
peak plasma concentrations of approximately 25 ng/mL 35 mechanism and delivery tube are ?lled. Up to seven or eight
activations are required to prime the device. It is also
Were not observed until approximately 2.4 hours after
indicated that further priming to disperse one or tWo sprays
administration With a bioavailability of 99.8%. (Greenblat,
is to be performed if the device is not used for 48 hours or
et al., Journal of Pharmaceutical Sciences, Vol. 66, No. 1

(1979).) It has also been reported that, folloWing intranasal

longer. These procedures necessarily result in the dispenser

administration of loraZepam in a Cremophor EL, a non

being over?lled in order to assure that there Will be suf?cient
liquid to deliver the labelled number of doses. It has been
found that a substantial volume of the controlled substance
often remains in the device, even after the labelled number
of doses have been administered. In practice, it has also been
found that medical personnel and Workers at health care

aqueous vehicle, the time to peak plasma concentration Was
1.4 hours With a bioavailability of 51%. (Lau and Slattery,

International Journal of Pharmaceuticals, 54 (1989)

171—174.)
The intranasal route of administration also provides
numerous advantages over intravenous (IV) and intramus

45

steriliZation of the hypodermic syringe and in the institu

Well-knoWn among medical facility managers and laW

tional setting, leads to concerns among medical personnel
about the risk of contracting disease if the they are acciden

tally stuck by a contaminated needle. Strict requirements for
the safe disposal of the used needle and syringe must also be
imposed in the institutional setting. In contrast, intranasal
administration requires little time on the part of the patient
and the attending medical personnel, and is far less burden

enforcement authorities. So far as is presently knoWn, no
preventative measures have been reported that are effective

in dealing With this problem.
A further problem resides in dispensing to a patient
55

not act rationally in self-administering a drug for relief of the
symptom, there is a potential for overdosing. Moreover,

institutional setting that is associated With nasal spray
devices.
A second important advantage of intranasal administra
tion over IM and IV is patient acceptance of the drug

because of the nature and construction of these multiple dose

spray devices, medical personnel cannot easily determine

delivery system. Many, if not most, patients experience
anxiety and exhibit symptoms of stress When faced With

cases, the after-effects of the injection include burning,
edema, sWelling, turgidity, hardness and soreness. In

intranasal spray devices With suf?cient ?uid contents for
numerous doses for anxiety control purposes. Because a

patient suffering from a disorder and exhibiting anxiety may

some on the institution than injectables. There is no signi?
cant risk of infection of medical personnel or others in the

hypodermic injections via the IM or IV routes. In some

facilities routinely abscond With the dispensers, sometimes
after the patient has had only one or a feW of the prescribed
doses in a multi-dose container. This improper use of
controlled substances as so-called “recreational drugs” is

cular (IM) injections. One principal advantage of intranasal
administration is convenience. An injectable system requires

65

the number of doses that have been administered by a simple
visual inspection of the device.
Another problem that has recently been identi?ed in
clinical studies is the relative inaccuracy of multi-dose
intranasal delivery devices that are currently being marketed
With opiate solutions for the control of pain. Not only does

US 6,610,271 B2
3

4

the average volume of liquid spray actually administered fall
about 10% below the purported dosage appearing on the
approved label for one such product, signi?cant variations

amount, or an amount that is so small that it cannot be
recovered for a subsequent unintended use or abuse after the

prescribed use.
As used herein, the term “spray” means the liquid com

Were also observed among a series of administrations by

each patient in the study group. Thus, spray devices tested

position expressed from the device under pressure in the

containing an opiate compound classed as a “controlled
substance” by the FDA Were found to be capable of admin

form of an aerosol, a ?ne mist, liquid droplets, a ?ne stream,
and combinations of tWo or more of the above forms. It Will

istering only about 90% by volume of the prescribed dosage,
on average, and the dosage actually received by each patient
in repeated administrations exhibited substantial signi?cant
variations of from 60% to 130% of the claimed label dosage.

be understood that the precise form of the composition is

dependent upon the viscosity and other physical properties
10

OBJECTS OF THE INVENTION

Accordingly, it is a principal object of the invention to

provide a novel therapeutic composition of loraZepam and
its pharmaceutical by acceptable derivatives for intranasal

of the composition and the manner in Which the manual or

other force is applied to the device to discharge the liquid
composition. A heterogenous spray is acceptable so long as
the sprayed volume is effectively adsorbed by the nasal
mucosa.

15

administration of at least one predetermined volumetric unit

As used herein, “loraZepam” means loraZepam and its
active pharmaceutically acceptable derivatives and metabo

dose in the form of a spray by means that delivers one or

lites.

more therapeutically prescribed unit doses that are highly

SUMMARY OF THE INVENTION

accurate as to the volume discharged and Which leave no

signi?cant quantity of the composition in the delivery

20

Another object of the invention is to provide a novel

ethylene glycol having an average molecular Weight of 400,
[“PEG 400” ] and diluting the solution With propylene

composition comprising loraZepam, a knoWn compound that
is approved for oral, IM and/or IV administration, for use in
a highly accurate and reproducible intranasal spray delivery
system in a single unit-dose or therapeutically prescribed

25

multiple unit-dose.
It is a further object of this invention to provide an

improved intranasal dosage composition and method of
administration of loraZepam that exhibits a relatively rapid
onset, moderate duration of therapeutic activity, minimal
side effects, improved bioavailability, ease and safety of
administration, and minimal physical discomfort and anxi
ety to the patient occasioned by administration.
It is another object of this invention to provide an intra

The improved loraZepam composition for intranasal spray

administration is prepared by dissolving loraZepam in poly

means.

30

glycol to a ?nal composition of about 20% PEG 400 and

80% propylene glycol 2 by volume.
The invention further comprehends the intranasal admin
istration of the loraZepam composition in the form of a spray
in a unit-dose of a predetermined therapeutic volume, Where
substantially all of the predetermined volume of the com
position is sprayed from delivery means Within a speci?ed
narroW range of accuracy, While leaving essentially no

signi?cant quantity of the therapeutic composition in the
applicator from the unit-dose as administered. The dose is
35

administered principally in the form of liquid droplets, that
may be accompanied by a minor proportion of an atomiZed

nasal delivery system for one or more unit doses of novel

mist or an aerosol. Application to the nasal mucosa of a

therapeutic compositions containing loraZepam that permits

subject requiring treatment is consistent With the current
therapeutic use of loraZepam for treatment of anxiety-related
disorders, and especially useful When acute administration is
indicated. Such indications include sedation of agitated

administration of one or more therapeutically prescribed
unit-doses in a medical care facility, such as a hospital, day
clinic, or doctor or dentist’s of?ce in Which the delivery

40

and/or demented patients pre-operative surgical/dental seda

system contains essentially no signi?cant quantity of the
therapeutic composition after administration of the single
unit-dose or the prescribed number of multiple unit-doses.
It is also an object of the invention to provide the novel
and improved combination of a device for intranasal admin

tion and administration to children.

The loraZepam compositions administered in accordance
45

temic pharmacological effects folloWing absorption from the

istration and a formulation for loraZepam that meet the

nasal mucosa. As Will be shoWn beloW, the novel pharma
ceutical composition provide the loraZepam in a form that is
readily absorbable by the nasal mucosa Without damaging or
irritating the mucosa, or producing an allergic, or other

requirements for FDA approval.
Yet another object of the invention is to provide such

novel loraZepam compositions for intranasal administration
in a relatively small and inexpensive, manually operated,
self-contained hand-held disposable device that retains
essentially no signi?cant quantity of the therapeutic com

unacceptable reaction in the recipient.
The loraZepam compounds for use in the practice of the
invention comprise a pharmacologically acceptable carrier

position after administration of the one or more unit-doses as

prescribed.

55

A further object of the invention is to provide a compre

hensive method for providing a novel therapeutic composi
tion for intranasal administration that contains loraZepam in
a form that exhibits the same pharmacological activity as

loraZepam compositions that are approved for oral, IM
and/or IV administration, the intranasal composition being
available for delivery in highly accurate and reproducible
predetermined unit-doses leaving essentially no signi?cant
quantity of the therapeutic composition after administration
of the prescribed number of unit-doses.
As used herein, the term “essentially no signi?cant quan
tity of the therapeutic composition” means none, or a trace

With the method and system of the invention exhibit sys

60

that can be nasally administered With safety over the entire
reasonably foreseeable range of prescribed users of the
composition. It has been found that the addition of Water to

the composition reduces the stability of the loraZepam. It is
therefore preferred that the liquid composition be non
aqueous. Compatible organic solvents ar preferred.
In one preferred embodiment, the loraZepam composition
includes minor proportion of an arti?cial sWeetener. The
purpose of the arti?cial sWeetener is to counteract or mask

the otherWise bitter taste that the subject can experience if
the composition reaches the taste buds. Flavor extracts can
65 also be included in the composition, either in addition to or
in place of an arti?cial sWeetener to mask the after taste of

the loraZepam composition. The composition preferably has

US 6,610,271 B2
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a shelf life in the chosen delivery system of at least six
months, and most preferably greater than tWo years.

The preparation of the loraZepam composition and its
aseptic ?lling into containers and the assembly of the ?lled

Optionally, the composition can include one or more pre

containers in the spray devices must be completed under

servatives of the type approved for use in pharmaceutical
compositions. The preservative is preferably an anti
oxidant. One preservative that has been found particularly
suitable is butylate hydroxytolune, Which can be added at the
rate of 0.1 mg/mL.
The loraZepam composition of the invention is also com

aseptic conditions since the loraZepam cannot Withstand
terminal steriliZation Without decomposition. Spray devices

patible With the delivery system. The loraZepam composi
tions for use in the invention are formulated to deliver the

can be steriliZed before ?ling, along With the intended
packaging, employing methods and technology that are Well
knoWn in the art.
10

The novel features and other advantages of the present
invention, in addition to those mentioned above, Will

dose Within the foreseeable temperature ranges of exposure,
e.g., Without becoming too viscous to be administered in the
proper form by the device, or crystalliZing at loWer tem

peratures; and Without exceeding the internal pressure limits

of the delivery system at higher temperatures.
The predetermined therapeutic volume of the pharmaceu
tical composition contained in the unit dose is delimited by
several parameters, including the capability of the nasal
passage to receive and absorb the volumetric quantity of

spray; and the solubility of the particular loraZepam in the

BRIEF DESCRIPTION OF THE DRAWINGS

become apparent to those skilled in the art from the folloW
15

ing detailed description and in conjunction With the accom

panying draWings, in Which:
FIG. 1 is a graphic representation of the concentration of
loraZepam in blood plasma versus time for IV, IM and IN

doses; and
20

physiologically and pharmacologically acceptable carrier

FIG. 2 is a graphic representation of the data of FIG. 1
over a longer time period.

liquid at the concentration required to achieve the desired

effect. The relative safety of administering a given prede
termined quantity of loraZepam to classes of patients for
anxiety-related disorders or for sedation, Whose body
Weight, age, general health, use of other medications may

DETAILED DESCRIPTION OF THE
PREFERRED EMBODIMENT
25

vary Widely and can be determined by methods Well knoWn
in the art.

Dispensing devices meeting the above criteria and tech
nical speci?cations have been provided in accordance With

30

the invention by modifying commercially available devices,
such as those sold by Pfeiffer of America of Princeton, N].
and Valois of America, Inc. of GreenWich, Conn. When
modi?ed as described beloW, such devices have the capa

bility of consistently delivering a predetermined volumetric

Laboratories under the brand name Ativan®, includes 2 mg
35

of loraZepam in 0.18 mL of polyethylene glycol 400 in
propylene glycol With 2.0% benZyl alcohol as a preservative.
This composition Was not acceptable for intranasal spray
administration because benZyl alcohol is irritating to the

dispenser that is manually operable by the patient requiring

mucosa.

40

can thereafter be discarded Without concern that others may

abuse the controlled substance.
Commercial spray devices can be provided With enough
pharmacologically active composition to administer one
predetermined unit-dose or tWo unit-doses (“bi-dose”), each

vide the desired unit-dose in a total sprayed liquid volume
that can be delivered by the device and accommodated and
absorbed by the subject’s nasal mucosa. LoraZepam is
insoluble in Water. A commercially available injectable

composition approved by the FDA and sold by Wyeth

amount of a liquid composition intranasally via a unit-dose

such intranasal drug administration. These manually oper
able devices are designed for delivery of a single unit-dose,
after Which there is essentially signi?cant quantity of the
therapeutic composition remaining in the device. The device

A suitable liquid composition for use in a spray device for
intranasal administration includes a solvent in Which the
desired concentration of loraZepam can be attained to pro

A suitable composition for use in the invention Was
prepared as folloWs.
LoraZepam Was formulated in a liquid composition for
use in the practice of the invention. Since loraZepam is

insoluble in Water, the loraZepam Was dissolved in polyeth
45

ylene glycol having an average molecular Weight of about
400 (“PEG400”), and the solution diluted With propylene

With a high degree of accuracy and reproducibility for the

glycol. In order to provide for shelf-life stability over a
period of up to six-months under typical conditions, a

device and among a plurality of such commercially manu
factured and ?lled devices.

preservative can be added. In a preferred embodiment, an
arti?cial sWeeter is also dissolved in the composition. The
?nal composition Was as folloWs:

In accordance With the invention, the ori?ce of a com

mercial spray applicator Was enlarged and the sWirl chamber
is retained in order to produce a spray that is principally in
the form of liquid droplets that coat the nares. A minor
proportion of the product may be in the form of a mist or
aerosol. The siZe of the ori?ce is optimiZed in relation to the

55

viscosity of the loraZepam composition.
Devices that are suitable for use in the practice of the
invention are fabricated from a variety of polymeric

materials, and can also include glass or polymer containers

60

lorazepam
polyethylene glycol 400
propylene glycol
butylate hydroxytolune
saccharin (powder)

10.0
0.18
0.809
0.1
1.0

mg
mL
mL

mg
mg

The loraZepam is preferably prepared in the form of a

for the liquid loraZepam composition and metal components,

single or unit-dose nasal spray for intranasal administration

preferably of stainless steel, that form elements of the
delivery system. Such devices are compact, relatively inex

by a precision dosage manually-activated pump. Each 1 ml

pensive and can be discarded after the prescribed use. In a

preferred embodiment, the container and its sealing means
are steriliZable; most preferably, the entire device is con
structed from materials that can be steriliZed.

65

of nasal spray solution is preferably formulated to contain 10
mg loraZepam. In a preferred delivery system, each actua
tion of the nasal spray pump delivers 0.1 ml of this 10 mg/ml
hm solution constituting a 1 mg dose. A smaller dose of the
loraZepam HCl can be administered to children.

US 6,610,271 B2
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As Will be understood by those familiar With the art,
dosage forms at lower concentrations of loraZepam can be
prepared for administration based upon the patient’s loWer

results of these studies of the methods and system of the
invention and the comparative prior art method folloW.
Unit-Dose:
A statistical comparison of dose 1 and dose 2 for the
Pfeiffer unit dose delivery system Was done using a paired

body Weight, as in the case of children or adults of substan

tially smaller siZe. The nasal spray solution has a pH in the
range of from about 3 to about 7, With a pH of about 5 being

t-test. Analysis of the data for normally functioning devices

preferred.

indicated that the difference betWeen the mean sprays of the
tWo applications using the Pfeiffer device Was not statisti

The loraZepam composition Was placed in containers
adapted for use With modi?ed Pfeiffer dispensers identi?ed
by model/part numbers as 52020/BSK 7482. The intranasal
applicators of the prior art are modi?ed by increasing the

10

A clinical study Was undertaken for the purposes of (1) to

siZe of the discharge ori?ce in nose piece to about 0.07 mm
from about 0.05 mm in diameter (Which is typical for an

aqueous solution), i.e., a 40% increase in diameter. This
increase is necessary to accommodate the higher viscosity of
the composition of the invention. The sWirl chamber of the
prior art precision spray dispenser can be retained. The
applicator components are steriliZed by methods Well knoWn
in the art. As Will be understood by those of ordinary skill
in the art, other changes in the design and/or construction of

15

20

TWelve healthy non-smoking subjects (siX male and siX
female) betWeen the ages of 18 and 35 years Were initially
25

and physical eXam, laboratory tests, and other customary

procedures.
The subjects Were Within 120% of ideal body Weight and

conditions is important. The optional inclusion of a preser

no history of allergies, acute or chronic nasal symptoms,
signi?cant nasal surgery or abnormalities Were reported.

vative Will serve to eXtend the shelf life, as Will storage

under refrigeration. In the last case, the products and dis

Eleven of the tWelve subjects completed the study accord
ing to the protocol. Each of the subjects received 3 doses of
2 mg of loraZepam on three separate occasions. No clinically

penser should be brought to room temperature before admin

istration. Any expired product is discarded in the appropriate
manner.

cially produced and sold by Pfeiffer of America, Inc., each

selected for this inpatient study. One subject left the study
and one subject received delayed doses. Study participants
Were selected based on inclusion/exclusion criteria, history

life. If the applicator body is not transparent, visual inspec
tion of the drug product for signs of deterioration is not
possible and attention to the eXpiration date and storage

the form of a liquid composition at a concentration of 1.0 mg
of loraZepam in 0.1 mL. The composition Was used to ?ll the
required number of single-dose, metered sprayers commer

crossover, randomiZed, pilot bioavailability study of
loraZepam comparing intranasal administration in healthy
human volunteers.

discharge the more viscous composition of the invention.
The loraZepam nasal spray applicators are preferably

A formulation of loraZepam for intranasal administration
Was prepared as described above under aseptic conditions in

assessing the absolute bioavailability of loraZepam by com
paring the pharmacokinetics of 2.0 mg loraZepam adminis
tered by intranasal (IN) and intravenous (IV) routes; and (2)
to compare pharmacokinetic parameters via IN administra
tion to intramuscular (IM) and intravenous administration.
This Was undertaken as a single-dose, open-label, three-Way

the spray dispenser can be made to accommodate and

stored
and areatprotected
temperatures
frominlight
the range
to provide
of 2°—8°
for maXimum
C. (36°—48°
shelf

cally signi?cant. (This analysis eXcluded data from one of
the devices that malfunctioned.)
Investigational Methods

35

signi?cant protocol violations occurred during this study.
The inclusion criteria mentioned abstinence from prescrip

tion and non-prescription drugs prior to and during the study,

40

and any medications taken in the 14 days before the study
and during the study Were noted. Subjects abstained from
alcoholic and caffeine-containing beverages for 48 hours

before the dosing period and during the study.

of Which sprayers ?rst having been modi?ed as described

Clinical Trials

above. The ?lling of the containers and their assembly is

Study Drug Formulation

completed under aseptic conditions since the loraZepam
composition cannot Withstand the heat of steriliZation.
Each subject received a single spray in each nostril for a
total of 2.0 mg. A 2.0 mg dose is preferred as being Within
common, safe and labeled doses prescribed. Commercially
available loraZepam Was purchased for IM and IV admin
istration. The product Was Ativan® Injection for parental

LoraZepam for intranasal administration Was supplied by
45

LoraZepam for intravenous administration (“IV”) Was sup
plied as Ativan® 1 mg/mL for subjects 1, 3, 8, and 9 on the
?rst day and for subjects 2, 4, 5, 6, and 7 on the second study

day. LoraZepam for intramuscular administration (“IM”)
Was supplied as Ativan® 2 mg/mL for subjects 2, 4, 5, 6 and
7 on ?rst study day and for subjects 1, 3, 8 and 9 on the

administration sold by Wyeth Laboratories, (a Wyeth-Ayerst

second study day. Free base content Was 1.77 mg or 88.7%

Company.) Each mL of Ativan® Injection is formulated With
2 mg of loraZepam in 0.18 mL PEG400 in propylene glycol

of stated loraZepam strength (from molecular Weights:
321.8—36.46=285.34, 285.34/321.8=88.7%) To summarize,

With 2.0% benZyl alcohol as a preservative. The IV doses

Were diluted according to the label instructions by adding

55

Treatment A: 2.0 mg intravenous loraZepam;
Treatment B: 2.0 mg intramuscular loraZepam; and
Treatment C: 2.0 mg intranasal loraZepam solution

Each of the applicators Was Weighed prior to use and after

use. Quali?ed medical personnel took the respective appli
cators to subjects in a clinical setting; one dose Was admin
60

Study Drug Administration
Drug administration occurred at approximately 0800
hours folloWing overnight fasting. Subjects Were alloWed up
to 360 mL of juice or soft drink one hour before each dose,

through antecubital veins on the arm opposite to the arm

from Which samples Were taken, injecting the solution over
about ?ve minutes. Syringes Were Weighed before and after
administration. Further details of the protocol, and the

the dosages for each of the three routes of administration
Were as folloWs:

one mL of Water.

istered up each nostril, after Which the applicator Was
recovered for Weighing. Each subject used tWo Pfeiffer unit
dose spray devices, both of Which Were discarded folloWing
the post-use Weighing. The IV doses Were administered

the University of Kentucky College of Pharmacy.

but Were not alloWed to eat for one hour after their dose.
65

Safety Measures
Weight, blood pressure, and pulse Were measured prior to
dosing and at the end of the study. Blood pressure and pulse

US 6,610,271 B2
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rate Were measured With the subjects seated in an upright

position before any corresponding blood sample Was col

TABLE 1

lected. Blood pressure and pulse rate Were measured and
recorded on the same arm throughout the study at 0 (pre

Mean (CV as a %) pharmacokinetic parameters following
administration of 2 mg intravenous (IV infusion over 5 min),

dose) and 30 minutes, 1, 2, 4, 8, and 16 hours.

intranasal (IN) and intramuscular (IM) lorazepam doses in

The three treatments Were separated by one-Week Wash

11 healthy volunteers.

out period. The subject (#02) Whose doses Were delayed
received the ?nal dose Within one month of the ?rst dose,
Was dosed With the other subjects during their ?rst and third
periods and received the ?nal treatment tWo Weeks later. She

Parameter

Tmax (hrs*)
10

cmax (ng/mL)
t1), (hr)
AUc.H

Was dosed in the treatment order to Which she Was random

iZed.
Clinical Adverse Events

Spontaneously reported adverse events Were recorded by
the subjects throughout the study; adverse events Were also
elicited by nondirected intervieWs.

2 mg IV

0.1

2 mg IM

3.0

2 mg IN

0.5

(0.083 to 1.017)
47.57 (57.8)
16.6 (27.3)
386.8 (19.4)

(0.5 to 8.017)
22.58 (28.9)
17.4 (38.1)
372.8 (16.4)

(0.25 to 2)
21.38 (24.3)
18.5 (28.3)
288.0 (25.4)

500.8 (30.8)

506.2 (33.7)

393.5 (38.0)

4.3 (27.0)

4.3 (28.5)

5.7 (31.8)

(ng - hr/mL)

AUCM
15 (ng - hr/mL)

CL or CL/F (L/hr)

Sample Collection and Handling

vSS (L)

93.2 (11.9)

vZ or VZ/F (L)

97.8 (15.2)

99.2 (10.8)

140.1 (16.8)

assume 100%

100.9 (10.2)

77.7 (11.1)

F (%

_

_

Blood samples for the three treatments Were collected

from each subject according to the folloWing schedule: 0

20

(pre-dose), 5, 15, 30 and 45 minutes, and 1, 2, 3, 4, 8, 12, 18,

*median and range given for Tmax

Table 1 is a summary of pharmacokinetic data for the

24 and 36 hours folloWing loraZepam administration. The

three doses. Absorption of loraZepam folloWing IN admin

beginning of the IV administration Was considered time
Zero. After collection, the blood Was centrifuged in a refrig

istration Was rapid as indicated by the fact that concentra
tions Were detected in all subjects Within ?ve minutes after
the IN administration. The median Tmax values Were 30
minutes and three hours for the IN and IM doses, respec

erated centrifuge at 4° C. to separate the plasma and the
cells, and the plasma Was transferred to polypropylene tubes.
The plasma Was stored at approximately —70° C. at the study
site until shipped to an independent analytical service. The
plasma Was maintained froZen during shipping and upon
arrival at the remote analytical facility, the samples Were
stored at approximately —20° C. until analyZed.

25

tively. On average, 0.1091 g (CV 5.6%, n=21) Was dis
pensed from the individual spray pumps as determined by

the difference in the pre- and post-Weights. (This data
30

Bioanalytical Methods
LC/MS/MS Assay for LoraZepam
The sample analysis using an LC/MS/MS assay Was
performed by an independent service in accordance With
established protocols. The analytic range for the loraZepam

35

loraZepam concentration versus time graphs folloWing three
treatments: (A) 2.0 mg loraZepam by ?ve minutes IV
infusion, (B) 2.0 mg loraZepam IN dose and (C) 2.0 mg

method Was 0.10 ng to 25.00 ng/mL using 1.0 mL of human

plasma. Concentrations less than 1.10 ng/mL Were reported
as beloW quantitation limit (BQL). Samples With concen
trations greater than 25 ng/mL Were reanalyZed using a

excludes one malfuctioning device of the 22 devices used in
this study.) The mean plasma concentration versus time
curve pro?les for the IV, IM and IN doses are shoWn in FIG.
1. Plasma concentrations Were still detectable 36 hours after
administration.
FIGS. 1 and 2 are plots of the mean (n=11) plasma

40

loraZepam IM dose. FIG. 1 shoWs the results over the period
folloWing administration; FIG. 2 is the same data for the 36

hours folloWing administration.

dilution so that the assayed concentration Was Within the
Safety Results
range of 0.10 ng to 25.00 ng/mL.
Results of the clinical measurement of vital signs and
Pharmacokinetic Methods
body Weight exams Were recorded and nasal exams Were
Plasma concentration versus time date for loraZepam Were 45 performed. A revieW of this data failed to reveal any
clinically signi?cant safety concerns. There Were no serious
analyZed using noncompartmental pharmacokinetic meth
adverse events and no subjects Were discontinued due to
ods. Pharmacokinetic parameters Were determined using

standard noncompartmental methods With log-linear least

adverse effects. Subjects commented that they experienced

square regression analysis to determine the elimination rate

a mild bad taste immediately after the IN dose. Any safety

constants (WinNonlin, Pharsight Corp., Palo Alto, Calif.).

concerns associated With IN are similar to those associated

The areas under the concentration versus time curves from

With IV administration.
Detailed nasal examination demonstrated no pathology of

time Zero to in?nity (AUCO_OO) Were calculated by a com

the naso-pharynx after single administration of the

bination of the linear and logarithmic trapeZoidal rules, With
extrapolation to in?nity by dividing the last measurable
serum concentration by the elimination rate constant ()tz.)

loraZepam formulations.
55

The plasma loraZepam concentrations and actual collec

(Proost, 1985). Values for the maximum concentration
(Cmwc) and time to Cmax (Tmax) Were determined by visual

tion times for each of the 11 subjects Was tabulated and
plasma concentration-time curves for each of the 11 subjects

inspection of concentration versus time data for each sub
ject. The elimination half-life Was determined from 0693/

K2. The absolute bioavailability
for the IN and IM dosage
forms, assuming equal 2 mg doses, Was determined by
F=AUCIN)O_OO/AUCIV)O_OO for the IN dose and F=
AUCIMD_OO/AUCW)O_Oo for the IM dose. Clearance (CL for IV
and CL/F for IN and IM doses) Was determined by dividing
the dose by AUCO_OO. Volume of distribution at steady state
and for elimination (V55 and V2) Were determined by
moment curves (Gibaldi and Perrier, 1982).

Pharmacokinetic Results

Were prepared. The mean concentration-time curves of
60

FIGS. 1 and 2 are representative for most subjects (mean
data tabulation). FIG. 1 is a plot of the mean (n=11)

loraZepam concentration versus time graphs folloWing IV,
65

IM and IN doses of 2 mg loraZepam during the 4 hours after
dose; FIG. 2 is the same data plotted for 36 hours after the
dose.
Noncompartmental pharmacokinetic analysis Was used to
evaluate the plasma concentration versus time curves of

US 6,610,271 B2
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loraZepam following single 2.0 mg doses of loraZepam by
intravenous (IV), intramuscular (IM), and intranasal (IN)

the propylene glycol constitutes from about 75% to
about 85% by volume of the composition, a sWeetener,

routes. Individual plasma loraZepam concentration versus
time pro?les for all subjects Were recorded; number of time

and
a preservative,

points used to estimate the elimination rate constant Were

Wherein the loraZepam is present in the liquid composi

also recorded; and a complete listing of individual and mean
pharmacokinetic parameters for all 11 subjects Was
recorded. Table 1 is a summary of the descriptive statistics

tion at a concentration of about 1.0 mg/0.1 mL.

7. The composition of claim 6, Wherein the polyethylene
glycol has an average molecular Weight of about 400.
8. The composition of claim 7, Wherein the ratio of

for loraZepam pharmacokinetic parameters.
Rapid absorption of loraZepam Was observed after the IV
and IN doses. The Tmwc values Were approximately 9 and 18
minutes, on average, for the IM and IN doses, respectively.

10

polyethylene glycol to propylene glycol is about four-to
one.

9. The composition of claim 7, Wherein the solvent

The mean Tmax for the IV infusion Was not the ?rst blood
constitutes about 80% by volume and the propylene glycol
sample after the end of the infusion for tWo reasons. The
about 18% by volume.
peak concentration after the IV dose in one subject Was not 15
10. The composition of claim 6, Wherein the sWeetener is

at the ?rst blood sample after the end of the IV infusion, but
at the next time point. In the case of Subject 4, acquiring the
blood sample immediately folloWing the IV infusion Was

delayed resulting in the mean Tmax being affected. As
expected, the loraZepam Cmax and AUCs Were signi?cantly
higher after IM and IV administration compared to IN
administration. Mean plasma half-lives and clearance after

selected from the group consisting of saccharin and aspar
tame.

11. The composition of claim 10, Wherein the sWeetener
is saccharin.
20

13. A method of treating a mammal exhibiting symptoms

correcting for bioavailability, Were similar for all three

of anxiety-related disorders, said mammal requiring

treatments.

The arithmetic mean value of absolute bioavailability of

treatment, the method comprising the steps of:
25

loraZepam (11 subjects) for the IN formulation is 78%. The
plasma levels Were comparable to those of the IM dose.
From the above, it Will be understood that a novel
composition and method is provided for the safe and con
trolled intra-nasal administration of precise doses of

tially of:
30

loraZepam, polyethylene glycol and propylene glycol
as a solvent-carrier for the loraZepam; Wherein the

polyethylene glycol constitutes from about 15% to
about 25% by volume and the propylene glycol
constitutes from about 75% to about 85% by volume

men.

What is claimed is:
1. A pharmaceutical composition for intranasal adminis
35

physiological response in the mammal, the composition

of the composition, a sWeetener, and
c. administering a predetermined measured dose of the

liquid loraZepam containing composition intranasally

consisting essentially of:

to the mammal requiring treatment by spraying the

loraZepam;
polyethylene glycol and propylene glycol as a solvent
carrier for the loraZepam; Wherein the polyethylene
glycol constitutes from about 15% to about 25% by
volume and the propylene glycol constitutes from about
75% to about 85% by volume of the composition; and

a. providing an intranasal spray delivery device;

b. ?lling the delivery device With a sprayable liquid
composition, the liquid composition consisting essen

loraZepam in accordance With a medically prescribed regi

tration to a mammal that produces a sedative-anxiolytic

12. The composition of claim 6, Wherein the preservative

is butylated hydroxytoluene.

liquid composition droplets from the delivery device
40

into at least one of the mammal’s nostrils.

14. The method of claim 13, Wherein the dose is admin

istered by manually activating the delivery device.
15. The method of claim 13, Wherein the predetermined

dose is administered by spraying the loraZepam-containing

Wherein the composition forms a spray When discharged
from a manually actuated spray device.

composition ?rst in one nostril and then in the other.
16. The method of claim 13, Wherein the mammal is an
adult human and the predetermined dose is tWo Mg of

2. The composition of claim 1, Wherein the polyethylene

loraZepam.

a sWeetener,

45

17. The method of claim 13, Wherein the sprayable liquid

glycol has an average molecular Weight of about 400.

composition is prepared by dissolving loraZepam in the

3. The composition of claim 1, Wherein the polyethylene
glycol constitutes about 20% by volume and the propylene
glycol about 80% by volume of the composition.
4. The composition of claim 3, Wherein the solvent-carrier
is polyethylene glycol having an average molecular Weight
of about 400.

5. The composition of claim 3, Wherein the loraZepam is

solvent carrier and adding the loraZepam in the solvent
carrier to the delivery device under aseptic conditions.
18. The method of claim 13 Which includes the further

step of steriliZing the delivery device before addition of the
55

liquid composition.
19. A pharmaceutical composition for intranasal admin

istration consisting essentially of:

present in the composition at a concentration of 1.0 mg/0.1

loraZepam;

mL.

6. A sprayable liquid pharmaceutical composition for

polyethylene glycol and propylene glycol; Wherein the

intranasal administration in the form of at least one unit-dose
to a mammal for the purpose of producing a sedative

polyethylene glycol constitutes from about 15% to
about 25% by volume and the propylene glycol con

anxiolytic response in the mammal, the composition con

stitutes from about 75 % to about 85 % by volume of the

sisting essentially of:

composition;

loraZepam;
polyethylene glycol and propylene glycol as a solvent for
the loraZepam; Wherein the polyethylene glycol con
stitutes from about 15% to about 25% by volume and

and a sWeetener.
65

20. A composition according to claim 19, Wherein the
polyethylene glycol has an average molecular Weight of
about 400.
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21. A composition according to claim 19, wherein the
polyethylene glycol constitutes about 20% by volume and
the propylene glycol about 80% by volume of the compo

27. A pharmaceutical composition for intranasal admin

istration consisting essentially of:
loraZepam 10.0 mg;

sition.

polyethylene glycol 400 0.18 mL;
propylene glycol 0.09 mL;
butylated hydroXytoluene 0.1 mg; and

22. A composition according to claim 19, Wherein the
loraZepam is present in the composition at a concentration of
1.0 mg/0.1 ml.
23. The composition of claim 19, Wherein the sWeetener
is saccharin, aspartame or combination thereof.

24. A pharmaceutical composition for intranasal admin

saccharin 1.0 mg.

28. Amethod of treating a mammal suffering from anxiety
10

istration consisting essentially of:

comprising intranasally administering a pharmaceutical
composition consisting essentially of:

loraZepam;

loraZepam;

polyethylene glycol and propylene glycol; Wherein the

polyethylene glycol and propylene glycol; Wherein the

polyethylene glycol constitutes from about 15% to
about 25% by volume and the propylene glycol con
stitutes from about 75% to about 85% by volume of the

composition;
a sWeetener, and a preservative.

25. A composition according to claim 24, Wherein the
sWeetener is saccharin, aspartame or combination thereof.

15

polyethylene glycol constitutes from about 15% to
about 25% by volume and the propylene glycol con
stitutes from about 75% to about 85% by volume of the

composition;
a sWeetener; and a preservative, Wherein the composition

achieves a plasma loraZepam Cmwc of at least 21 ng/ml
When administered intranasally.

26. A composition according to claim 24, Wherein the

preservative is butylated hydroXytoluene.

*

*

*

*
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